Boehringer Ingelheim acquires Funxional Therapeutics inflammation portfolio
08:33 EDT 26 Jul 2012 | Avakado
Boehringer Ingelheim and Funxional Therapeutics, have formed an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics’ FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a br..
Original Article: Boehringer Ingelheim acquires Funxional Therapeutics inflammation portfolio
More From BioPortfolio on "Boehringer Ingelheim acquires Funxional Therapeutics inflammation portfolio"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
